Beximco Pharmaceuticals Limited (DSE: BXPHARMA)

Market Cap	34.13B
Revenue (ttm)	43.08B
Net Income (ttm)	5.33B
Shares Out	446.11M
EPS (ttm)	11.95
PE Ratio	6.40
Forward PE	6.22
Dividend	3.50 (4.58%)
Ex-Dividend Date	n/a

Volume	1,001,689
Open	75.30
Previous Close	75.30
Day's Range	75.00 - 77.30
52-Week Range	71.40 - 146.20
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 4, 2024

About Beximco Pharmaceuticals

Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to ...

• Industry: Pharmaceutical Preparations
• Founded: 1976
• Employees: 5,700
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: BXPHARMA

Financial Performance

In 2023, Beximco Pharmaceuticals's revenue was 39.27 billion, an increase of 13.26% compared to the previous year's 34.67 billion. Earnings were 4.61 billion, a decrease of -9.94%.